Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1165-1172

  Dogliotti, L ^a   Berruti, A ^a   Buniva, T ^a   Zola, P ^a   Bau M G ^a   Farris, A ^a   Sarobba, M G ^a   Bottini, A ^a   Alquati, P ^a   Deltetto, F ^a   Gosso, P ^a   Monzeglio, C ^a   Moro, G ^a   Sussio, M ^a   Perroni, D ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LONIDAMINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 9244240959     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1165     Document Type: Article

References (30)

1. Bonadonna G, Gianni L, Santoro A, et al: Drugs ten years later: Epirubicin. Ann Oncol 4:359-369, 1993
2. Bumma C, Dogliotti L, Ciambellotti E, et al: 5-Fluorouracil, epirubicin, cydophosphamide (FEC) versus epirubicin in advanced breast cancer. Proc European Conference on Clinical Oncology 5:1011, 1989 (abstr)
3. Focan C, Andrien JM, Closon M Th, et al: Dose-response relationship of epirubicin-based first line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
4. De La Torre M, Hao XY, Larsson R, et al: Characterization of four doxorubicin adapted human breast cancer cells with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res 13:1425-1430, 1993
5. Floridi A, Paggi MG, Marcante ML, et al: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:497-499, 1981
6. Floridi A, Paggi MG, D'Atri S, et al: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41:4661-4666, 1981
7. De Martino C, Malorni W, Accinni L, et al: Cell membrane changes induced by lonidamine in human erithrocytes and T-limphocytes, and Ehrlich ascites tumor cells. Exp Mol Pathol 46:15-30, 1987
8. Ben-Horin H, Tassini M, Vivi A et al: Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. Cancer Res: 55:2814-2821, 1995
9. Zupi G, Greco C, Laudonio N, et al: In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res: 6:1245-1250, 1986
10. Citro G, Cucco C, Verdina A, et al: Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64:534-536, 1991
11. Savini S, Zoli W, Nanni O, et al: In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 24:27-34, 1992
12. Zupi G, Del Bufalo D: In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer line. Int J Oncol 4:737-740, 1994
13. Calabresi F, Marolla P, Di Lauro L et al: Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer patients. Results of a multicentric randomized clinical study. Int J Oncol 4:753-760, 1994
14. Tomirotti M, Bernardo G, Epifani C, et al: Recovery of response to Adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 3:213-217, 1993
15. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO offset publication. Geneva, Switzerland, UICC, 1978
16. Lee E, Desu M: A computer program for comparing k samples with right censored data. Computer Programs Biomed 2:315-321, 1972
17. Nie NH, Hull CH, Jeakins JG, et al: Statistical Package for the Social Sciences. SPSS Inc, Chicago, IL, 1988
18. Band PR, Maroun J, Pritchard K, et al: Phase II study of lonidamine in patients with metastatic breast cancer: A National Cancer Institute of Canada Clinical Trial Group Study. Cancer Treat Rep 70:1305-1310, 1986
19. Pronzato P, Amoroso D, Bertelli G, et al: Phase II study of lonidamine in metastatic breast cancer. Br J Cancer 59:251-253, 1989
20. Robins HI, Neuberg DS, Benson III AB, et al: Phase II study of lonidamine in metastatic breast cancer. Invest New Drugs 8:397-399, 1990
21. Segre G, Catanese B: Pharmacokinetics of lonidamine. Chemotherapy 27:77-84, 1981 (suppl 27)
22. Robustelli della Cuna G, Pedrazzoli P: Toxicity and clinical tolerance of lonidamine. Sem Oncol 18:18-22, 1991 (suppl 4)
23. Newell DR, Mansi J, Hardy J, et al: The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Sem Oncol 18:11-17, 1991 (suppl 4)
24. Teicher BA: Lonidamine: In vitro/in vivo correlations. Eur J Cancer 30A:1411-1413, 1994
25. Calabresi F: Drug Resistance: Lonidamine, in DeVita VT Jr, Hellman S, Rosemberg SA (eds): Cancer: Principles and Practice of Oncology Updates, vol 8 (no. 6). Philadelphia, PA, Lippincott, 1994
26. Lopez M, Carpano S, Di Lauro L, et al: Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas. Int J Clin Oncol 6:363-367, 1995
27. Habeshaw T, Jones R, Stallard S, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer. Results of a randomized trial. J Clin Oncol 9:295-304, 1991
28. The French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9: 305-312, 1991
29. Clark GM, Sledge GW Jr, Osborne K, et al: Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1:55-61, 1987
30. Zinser JW, Hortobagyi GN, Buzdar AU, et al: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5:773-782, 1987